Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report

被引：28

作者：

Altintas, Abdullah ^{[1
]}

Cil, Timucin

Kilinc, Ilhan

Kaplan, Muhammet Ali

Ayyildiz, Orhan

机构：

[1] Dicle Univ, Dept Hematol Oncol, TR-21280 Diyarbakir, Turkey

[2] Dicle Univ, Dept Med Oncol, TR-21280 Diyarbakir, Turkey

[3] Dicle Univ, Dept Internal Med, TR-21280 Diyarbakir, Turkey

[4] Dicle Univ, Dept Radiol, TR-21280 Diyarbakir, Turkey

来源：

JOURNAL OF NEURO-ONCOLOGY | 2007年 / 84卷 / 01期

关键词：

chronic myeloid leukemia; blastic phase; imatinib mesylate; meningeal leukemia;

D O I：

10.1007/s11060-007-9352-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of chronic phase CML. It has also shown activity in patients with CML in accelerated or blastic phases. However, the penetration of the drug and its active metabolites into the central nervous system (CNS) is poor. Therefore, the CNS is sanctuary site for malignant cells in patients treated with imatinib. Herein, we report a patient with CML in accelerated phase that developed central nervous system disease while on imatinib mesylate therapy.

引用

页码：103 / 105

页数：3

共 13 条

[1] CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid [J].

Bornhauser, M ;

Jenke, A ;

Freiberg-Richter, J ;

Radke, J ;

Schuler, US ;

Mohr, B ;

Ehninger, G ;

Schleyer, E .

ANNALS OF HEMATOLOGY, 2004, 83 (06) :401-402

[2] A STUDY OF PROGNOSTIC FACTORS IN BLAST CRISIS OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA [J].

CERVANTES, F ;

ROZMAN, M ;

ROSELL, J ;

URBANOISPIZUA, A ;

MONTSERRAT, E ;

ROZMAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (01) :27-32

[3] Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux [J].

Dai, HQ ;

Marbach, P ;

Lemaire, M ;

Hayes, M ;

Elmquist, WF .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (03) :1085-1092

[4] The molecular biology of chronic myeloid leukemia [J].

Deininger, MWN ;

Goldman, JM ;

Melo, JV .

BLOOD, 2000, 96 (10) :3343-3356

[5] CHRONIC MYELOGENOUS LEUKEMIA IN BLAST CRISIS - ANALYSIS OF 242 PATIENTS [J].

KANTARJIAN, HM ;

KEATING, MJ ;

TALPAZ, M ;

WALTERS, RS ;

SMITH, TL ;

CORK, A ;

MCCREDIE, KB ;

FREIREICH, EJ .

AMERICAN JOURNAL OF MEDICINE, 1987, 83 (03) :445-454

[6] Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies [J].

Nadal, E ;

Olavarria, E .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (05) :511-516

[7] Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (ST1571) [J].

Naito, K ;

Mori, T ;

Miyazaki, K ;

Tsukada, Y ;

Ikeda, Y ;

Okamoto, S .

INTERNAL MEDICINE, 2003, 42 (08) :740-742

[8]

Pfeifer H, 2003, CLIN CANCER RES, V9, P4674

[9] Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy [J].

Rytting, ME ;

Wierda, WG .

LEUKEMIA & LYMPHOMA, 2004, 45 (08) :1623-1626

[10] HIGH-INCIDENCE OF MENINGEAL LEUKEMIA IN LYMPHOID BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA [J].

SAIKIA, TK ;

DHABHAR, B ;

IYER, RS ;

NANJANGUD, G ;

GOPAL, R ;

NAIR, CN ;

NADKARNI, KS ;

ASHOKKUMAR, MS ;

DHOND, SR ;

ADVANI, SH .

AMERICAN JOURNAL OF HEMATOLOGY, 1993, 43 (01) :10-13

← 1 2 →